We observed that inhibitors of the RAS-MAPK pathway, in particular mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitors, can strongly increase the sensitivity of rectal cancer organoids and CRC cell lines to radiation. This evidence concerns the gene MAP2K1 and rectal cancer.